Heron Therapeutics | HRTX - Cash And Equivalent


Heron Therapeutics reported $26.12M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
ALKERMES USD 351.55M 37.02M Mar/2026
Alnylam Pharmaceuticals USD 1.71B 53.53M Mar/2026
Amarin USD 131.06M 3.6M Mar/2026
ANI Pharmaceuticals USD 311.18M 25.59M Mar/2026
Anika Therapeutics USD 41.02M 16.46M Mar/2026
Arrowhead Research USD 201.64M 112.94M Dec/2025
Eisai JPY 301.65B 16.27B Sep/2025
Emergent BioSolutions USD 111.7M 23.9M Dec/2023
Esperion Therapeutics USD 156.16M 11.69M Mar/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Heron Therapeutics USD 26.12M 2.53M Mar/2026
Insmed USD 582.19M 71.74M Mar/2026
Ligand Pharmaceuticals USD 115.08M 59.85M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Neurocrine Biosciences USD 266.5M 446.5M Mar/2026
Omeros USD 1.9M 2.36M Jun/2025
Pacira USD 144.31M 14.24M Mar/2026
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Ultragenyx Pharmaceutical USD 175M 246M Mar/2026
Veracyte USD 263.14M 99.44M Mar/2026
Vertex Pharmaceuticals USD 7.25B 638.6M Mar/2026